![]() ![]() Induction of remission was achieved in 37.8% (787 of 2083) of patients in the active arm compared with 26.5% (400 of 1509) in the placebo arm. In CD, the individual-patient data meta-analysis of the primary outcome included 11 trials of induction with 3592 patients ( Supplementary Table 1). Immunomodulatory medications at baseline, % (n/N) Table 1 Patients’ Characteristics in Crohn’s Disease and Ulcerative Colitis Trials Characteristic Primary outcome results remained unchanged when tested using alternative temporal cutoffs and when modeled for individual patient’s covariates, including prior anti–tumor necrosis factor exposure. ![]() In UC trials, both the proportional biologic/placebo remission-induction effect and the pooled biologic-placebo effect were stable, regardless of disease duration. The primary outcome, proportional biologic/placebo treatment effect on induction of remission, was not different in short-duration disease of ≤18 months (n = 589, odds ratio, 1.47 95% confidence interval, 1.01–2.15) compared with longer disease duration (n = 2857, odds ratio, 1.43 95% confidence interval, 1.19–1.72). In CD, remission induction rates were higher in pooled placebo and patients in active arms with short-duration disease of ≤18 months (41.4% ) compared with disease duration of >18 months (29.8%, meta-analytically estimated odds ratio, 1.33 95% confidence interval, 1.09–1.64). We included 25 trials, testing infliximab, adalimumab, certolizumab, golimumab, natalizumab, or vedolizumab (6168 patients with CD and 3227 patients with UC).
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |